carmoterol carmoterol carmoterol (inn; development codes ta-2005 and chf-4226) is a non-catechol experimental ultra-long-acting β adrenoreceptor agonist (ultra-laba) that was in clinical trials before 2010 when it has been withdrawn from further development based on evidence that the compound does not possess a competitive profile. carmoterolclinical dataother namesta-2005; chf-4226routes ofadministrationinhalationatc codenonelegal statuslegal status development terminated identifiers iupac name 8-hydroxy-5-amino]ethyl]-1h-quinolin-2-one cas number147568-66-9pubchem cid63952chemspider57545 yunii9810nul4d1chemblchembl1094785 ychemical and physical dataformulac21h24n2o4molar mass368.433 g·mol−13d model (jsmol)interactive image smiles c(cc1=cc=c(c=c1)oc)nc(c2=c3c=cc(=o)nc3=c(c=c2)o)o inchi inchi=1s/c21h24n2o4/c1-13(11-14-3-5-15(27-2)6-4-14)22-12-19(25)16-7-9-18(24)21-17(16)8-10-20(26)23-21/h3-10,13,19,22,24-25h,11-12h2,1-2h3,(h,23,26)/t13-,19+/m1/s1key:ihoxnoqmrzispv-yjymszousa-n preliminary studies indicated duration of its effect exceeding 24 hours after inhalation of 3 μg. the pharmacologic profile of this medication included the fact its potency in isolated guinea pig trachea is greater than that of formoterol and salmeterol. it is over 100 times more selective for bronchial muscle than myocardial tissue.